|
Inotuzumab Ozogamicin Clinical Trials
13 actively recruiting trials across 4 locations
Also known as: Besponsa, CMC 544, CMC-544, CMC544, INO +2 more
Pipeline
Phase 2: 9Phase 3: 1Phase 1/2: 3
Top Sponsors
- M.D. Anderson Cancer Center4
- Institute of Hematology & Blood Diseases Hospital, China2
- Children's Oncology Group2
- University of Chicago1
- Pfizer1
Indications
- Cancer13
- Refractory B Acute Lymphoblastic Leukemia3
- Recurrent B Acute Lymphoblastic Leukemia3
- B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative2
- B Lymphoblastic Lymphoma2
Other4 trials
Houston, Texas4 trials
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
M D Anderson Cancer Center
Phase 2
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
M D Anderson Cancer Center
Phase 1/2
Phase 1/2
Birmingham, Alabama3 trials
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
University of Alabama at Birmingham Cancer Center
Phase 2
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Children's Hospital of Alabama
Phase 3
Chicago, Illinois1 trial
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
University of Chicago Medical Center
Phase 2
Westwood, Kansas1 trial
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
The University of Kansas Cancer Center
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.